General Information of Drug (ID: DMLIT84)

Drug Name
BBT-021 Drug Info
Synonyms BBT-003; Erythropoietin IgG-Fc fusion proteins (anemia), Bolder BioTechnology Inc
Indication
Disease Entry ICD 11 Status REF
Anemia 3A00-3A9Z Investigative [1]
Cross-matching ID
TTD Drug ID
DMLIT84

Molecule-Related Drug Atlas

Molecule-Related Drug Atlas
Molecule Type:
DTT
Drug Status:
Approved Drug(s)
Clinical Trial Drug(s)
Discontinued Drug(s)
Drug Name Drug ID Indication ICD 11 Highest Status REF
Darbepoetin alfa DMMJTYW Anemia 3A00-3A9Z Approved [2]
Epoetin alfa DMKWB73 Anemia 3A00-3A9Z Approved [3]
Methoxy polyethylene glycol-epoetin beta DMK1LZD Kidney transplant rejection NE84 Approved [4]
RHuEPO DMALNG0 Solid tumour/cancer 2A00-2F9Z Approved [1]
ErepoXen DM9YI2C Anemia 3A00-3A9Z Phase 3 [5]
Epoetin zeta DM9QPOU Anemia 3A00-3A9Z Phase 3 [6]
Hematide DMUE843 Anemia 3A00-3A9Z Phase 3 [7]
Cibinetide DMCFLRH Depression 6A70-6A7Z Phase 2 [8]
GlycoPEGylated erythropoietin DM5JKCL Solid tumour/cancer 2A00-2F9Z Discontinued in Phase 2 [9]
Albupoietin DMXK4CI Anemia 3A00-3A9Z Terminated [10]
⏷ Show the Full List of 10 Drug(s)

Molecular Interaction Atlas of This Drug

Molecular Interaction Atlas

Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Erythropoietin Receptor (EPOR) TTAUX24 EPOR_HUMAN Stimulator [1]

References

1 URL: http://www.guidetopharmacology.org Nucleic Acids Res. 2015 Oct 12. pii: gkv1037. The IUPHAR/BPS Guide to PHARMACOLOGY in 2016: towards curated quantitative interactions between 1300 protein targets and 6000 ligands. (Target id: 1718).
2 A cytosolic domain of the erythropoietin receptor contributes to endoplasmic reticulum-associated degradation. Eur J Biochem. 1999 Jul;263(2):410-9.
3 2007 Standards, Options, and Recommendations: use of erythropoiesis-stimulating agents (ESA: epoetin alfa, epoetin beta, and darbepoetin) for the management of anemia in children with cancer. PediatrBlood Cancer. 2009 Jul;53(1):7-12.
4 2007 FDA drug approvals: a year of flux. Nat Rev Drug Discov. 2008 Feb;7(2):107-9.
5 Combination erythropoietin-hydroxyurea therapy in sickle cell disease: experience from the National Institutes of Health and a literature review. Haematologica. 2006 Aug;91(8):1076-83.
6 Long-term safety and tolerability of epoetin zeta, administered intravenously, for maintenance treatment of renal anemia. Adv Ther. 2008 Nov;25(11):1215-28.
7 Nat Rev Drug Discov. 2013 Feb;12(2):87-90.
8 Clinical pipeline report, company report or official report of the Pharmaceutical Research and Manufacturers of America (PhRMA)
9 Design of Homogeneous, MonoPEGylated Erythropoietin Analogs With Preserved In Vitro Bioactivity. Exp Hematol. 2006 June; 34(6): 697-704.
10 Clinical pipeline report, company report or official report of cogenesys.